Guy Rosenthal, Ph.D.
Guy Rosenthal is the Business Development Officer at UCLA Technology Development Group. In his role, Guy leads technology commercialization and corporate development efforts, amongst others, to advance the commercialization and investment in biopharmaceutical assets on UCLA campus, predominantly in the fields of immuno-oncology, immunology and computational biology.
Previously, Guy served as the Manager of Academic Affairs and Networks at Teva Pharmaceutical Industries (NASDAQ: TEVA) Global R&D headquarters. In his role, Guy led global external innovation with Teva's academic partners and led search and evaluation of technologies reporting to Teva President of Global R&D and Chief Scientific Officer. Prior to that, Guy served as a Research Associate at VBL Therapeutics (NASDAQ: VBLT), a biopharmaceutical company focused on the development of first in class treatments for immune-inflammatory diseases and cancer. Guy led research in the fields of cancer and cardiovascular diseases, managing the development of novel drug delivery systems.
In addition, Guy is also the Founder and Managing Director of The French Horn Fund, a nonprofit impact fund that invests in social enterprises and special-needs populations.
Guy holds a B.Sc in Biotechnology and a Ph.D in both Biochemistry and Molecular Biology as part of the Academic-Corporate Partnership Program, Faculty of Life Sciences at Bar Ilan University, Israel.